Login to Your Account

Special ASCO 2013 Edition

Synta's Data Confirm Phase III Design Despite Stock Tumble

By Jennifer Boggs
Managing Editor

Monday, June 3, 2013
Much-awaited data from Synta Pharmaceuticals Corp.'s mid-stage GALAXY-1 study left investors less than satisfied, as shares of the Lexington, Mass.-based biotech dropped 34 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription